Objective: To probe into the effects of adjuvant treatment of spleen amino peptide oral liquid on cellular immunity and inflammatory factors in children with severe pneumonia. Methods: A total of 85 children with severe pneumonia admitted to Xuzhou Children’s Hospital from Feb. 2016 to Mar. 2018 were randomly divided into the routine group (n=42) and the combined group (n=43). The routine group was treated with routine western medicine

while the combined group received spleen amino peptide oral liquid combined with routine western medicine. Changes of cellular immunity and inflammatory factors before and after treatment

clinical efficacy and adverse drug reactions of two groups were compared. Results: After treatment

the levels of CD4+

CD4+/CD8+ increased in both groups (P<0.05)

while the levels of CD8+

IL-10

IL-17 and TGF-β1 decreased (P<0.05). The levels of CD4+ and CD4+/CD8+ in the combined group were higher than those in the routine group (P<0.05)

and the levels of CD8+

IL-10

IL-17 and TGF-β1 were lower than those in the routine group (P<0.05). The total effective rate of the combined group was 97.67%

higher than 86.71% of the routine group

and the difference was statistically significant (P<0.05). There was no significant difference in the incidence of adverse drug reactions between two groups (P>0.05). Conclusion: Adjuvant treatment of spleen amino peptide oral liquid in the treatment of children with severe pneumonia can improve the cellular immunity

control the levels of inflammatory factors

enhance the clinical efficacy

with lower incidence of adverse drug reactions.